Volume 1,Issue 2
Observation on the Clinical Efficacy of Modified Danggui Shaoyao Powder Combined with Acupoint Embedding in the Treatment of “Phlegm-dampness Type” Ovulation Disorder Infertility in PCOS
Objective: To explore the clinical therapeutic effect of modified Danggui Shaoyao Powder combined with acupoint embedding thread in the treatment of infertility caused by phlegm-dampness type ovulation disorders. Methods: From January 2024 to May 2025, 98 patients with PCOS “phlegm-dampness type” ovulation disorders who met the research conditions were grouped in a 1:1 ratio. The control group (n = 48) was treated with modified Danggui Shaoyao Powder, Letrazole (LE), and metformin. Patients in the experimental group (n = 48) were treated with acupoint embedding on the basis of the above-mentioned medication, and the clinical efficacy of the two groups of patients was compared. Results: The pregnancy rate of patients in the experimental group after treatment was 69.39%, the ovulation rate was 93.88%, and the total effective rate was (93.88%), while that of the control group was only 59.18%, P < 0.05; The scores of blood lipid and insulin resistance in the experimental group after treatment were lower than those in the control group (P < 0.05). After treatment, the levels of acne, acanthosis nigricans, F-G hirsutism and BMI in the experimental group were lower than those in the control group (P < 0.05). After acupoint embedding therapy in the experimental group, the ovarian volume recovered significantly and the number of follicles decreased significantly. During the treatment period, the comparison result of the incidence of side effects between the experimental group and the control group was P > 0.05. Conclusion: In the treatment of PCOS patients with “phlegm-dampness type” ovulation disorders, the use of modified Danggui Shaoyao Powder combined with acupoint thread therapy can increase the pregnancy rate and ovulation rate of patients, improve the clinical symptoms of patients, regulate the volume of the ovary and the number of follicles at the same time, and does not increase the adverse reactions of patients with medication.
[1] Zhou Y, 2019, Comparison of the Therapeutic Effects of Different Doses of Progesterone in the Treatment of Anovulatory Menstrual Disorders. Chinese Journal of Primary Medicine, 26(14): 1755–1757.
[2] Yang F, Xie M, Che Y, et al., 2020, Comparison of the Efficacy of Ovulation Induction Protocols Under High Progesterone and Long Protocols in In Vitro Fertilization and Embryo Transfer for Patients with Polycystic Ovary Changes. Journal of Ningxia Medical University, 42(2): 175–179.
[3] Fu S, Qing Dynasty, 2002, Fu Qingzhu’s Female Examination Rhymes. China Press of Traditional Chinese Medicine, 2002(9): 42.
[4] Hou J, Yu J, et al., 2000, Research on the Treatment of Hyperandrogenism and Hyperinsulinemia in Polycystic Ovary Syndrome with Traditional Chinese Medicine Tiangui Formula. Chinese Journal of Integrated Traditional Chinese and Western Medicine, 20(8): 589–592.
[5] Shi L, Han N, 2004, Professor Chu Yuxia’s Experience in Treating Polycystic Ovary Syndrome. Sichuan Journal of Traditional Chinese Medicine, 22(1): 1.
[6] Chen L, Wang L, Wang X, 1999, Treatment of 30 Cases of PCOS by Strengthening the Spleen, Benefiting the Kidney and Resolving Phlegm. Jiangsu Journal of Traditional Chinese Medicine, 20(7): 31.
[7] Luo Y, Zheng G, 1995, Clinical Research on the Treatment of Menopausal Syndrome Mainly Based on Kidney Tonification. Chinese Medical Journal, 1995(2): 25.
[8] Cui L, He J, 2004, Experience in Treating Polycystic Ovary Syndrome. Shandong Journal of Traditional Chinese Medicine, 20(1): 15.
[9] Xiao C, 2006, Understanding and Treatment of Infertility Caused by Polycystic Ovary Syndrome. Jiangsu Traditional Chinese Medicine, 27(3): 8.
[10] Anonymous, 2003, Summary of the Experience of Professors Yang Zhengwang and You Zhaoling in the Diagnosis and Treatment of Polycystic Ovary Syndrome. Journal of Hunan University of Chinese Medicine, 23(4): 23.
[11] Anonymous, 2003, Clinical Experience of Professor Wan Zhaoxia and Professor Tan Yong in Treating Polycystic Ovary Syndrome. Heilongjiang Traditional Chinese Medicine, 5: 31.
[12] Lu H, Wang C, 2007, 31 Cases of Polycystic Ovary Syndrome Treated with Expectorant and Meridian Unblocking Formula. Tianjin Journal of Traditional Chinese Medicine, 24: 43.
[13] Tian P, Zhu L, Li L, 1999, 30 Cases of Polycystic Ovary Syndrome Treated with Modified Qigong Pills. Henan Journal of Traditional Chinese Medicine, 19(3): 44.
[14] Ni L, Gao H, 2002, Tonifying the Kidney, Drying Dampness and Resolving Phlegm for the Treatment of Polycystic Ovary Syndrome. Journal of Traditional Chinese Medicine, 30(2): 28.
[15] Xia Y, 2004, Modified Cangfu Daotan Decoction in the Treatment of 30 Cases of Obese Polycystic Ovary Syndrome. Tianjin Journal of Traditional Chinese Medicine, 21(2): 169.
[16] Cho L, Jayagopal V, Kilpatrick E, et al., 2005, The Biological Variation of C-Reactive Protein in Polycystic Ovarian Syndrome. Clinical Chemistry, 51: 1905–1907.
[17] Sharma A, Yousef M, 2005, Recent Development in Polycystic Ovary Syndrome. Progress in Obstetrics and Gynecology, 14: 227–239.
[18] Wijeyaratne C, Balen A, Barth J, et al., 2002, Clinical Manifestations and Insulin Resistance (IR) in Polycystic Ovary Syndrome (PCOS) Among South Asians and Caucasians: Is There a Difference. Clinical Endocrinology, 57: 343–350.
[19] Balen A, Glass M, 2005, What’s New in Polycystic Ovary Syndrome? Recent Advances in Obstetrics and Gynecology, 11: 147–158.
[20] Legro R, Kunselman A, Dodson W, et al., 1999, Prevalence and Predictors of Risk for Type 2 Diabetes Mellitus and Impaired Glucose Tolerance in Polycystic Ovary Syndrome: A Prospective Controlled Study in 254 Affected Women. Journal of Clinical Endocrinology & Metabolism, 84: 165–169.
[21] Jedel E, Kowalski J, Stener-Victorin E, 2008, Assessment of Health-Related Quality of Life: Swedish Version of Polycystic Ovary Syndrome Questionnaire. Acta Obstetricia et Gynecologica Scandinavica, 87: 1329–1335.
[22] Rizzo M, Berneis K, Spinas G, et al., 2008, Long-Term Consequences of Polycystic Ovary Syndrome on Cardiovascular Risk. Fertility and Sterility, 91(4): 1563–1567.